AbbVie's statement on racial injustice

We are committed to advancing racial equality, through our continued
growth and acceptance of each other, our way of doing business, our
attraction and development of talent, and our service to the
community.

22%

By putting patients first, we explore new medical innovations and ways
to enhance access

If we bring a new medicine to market, it can help patients
worldwide, as opposed to the 20 or so patients we might see in
clinic in one day. That's what drives me. It's the greater impact we
can have by working here at AbbVie.

Kyle Holen, M.D., Head, Development Design Center

AbbVie combines advanced science, expertise and passion to solve the
world’s most serious health issues and have a remarkable impact on
people’s lives

2019 Dow Jones Sustainability World Index

AbbVie was named to the DJSI World Index for the seventh year in a
row for our responsible economic, environmental and social
performance

2018 Civic 50

For the fifth year in a row, AbbVie was recognized as one of
America’s most community-minded companies and honored for our
commitment to improve quality of life in communities where we live and work

DiversityInc Top 50 Companies for Diversity 2018

AbbVie has been recognized as one of the 50 most diverse companies
for the sixth year straight. This list includes companies excelling in
areas of recruitment, talent development, leadership, commitment and
supplier diversity

Unless otherwise specified, all product names appearing in this
internet site are trademarks owned by or licensed to AbbVie Inc., its
subsidiaries or affiliates. No use of any AbbVie trademark, trade
name, or trade dress in this site may be made without the prior
written authorization of AbbVie Inc., except to identify the product
or services of the company.

You are about to leave the AbbVie website

The product-specific site Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals that are not approved in other countries or region. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence. The Internet site that you have requested may not be optimized to your screen size. Do you wish to continue to this product-specific site?

Yes

No

You are about to leave for a 3rd party website

The link below will take you out of the AbbVie family of websites. Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie. The Internet site that you have requested may not be optimized to your screen size. Do you wish to leave this site?

Yes

Disclaimer Notice - Important

Recommended Offer for Allergan plc (“Allergan”) by AbbVie Inc. (“AbbVie”) (the “Acquisition”) by means of a scheme of arrangement under Irish law (the “Scheme”). You are attempting to enter the section of this website that is designated for the publication of documents and information in connection with the offer by AbbVie for Allergan announced on June 25, 2019 (the “Offer”). ACCESS TO THIS SECTION OF THE WEBSITE MAY BE RESTRICTED UNDER SECURITIES LAWS IN CERTAIN JURISDICTIONS. THIS NOTICE REQUIRES YOU TO CONFIRM CERTAIN MATTERS (INCLUDING THAT YOU ARE NOT RESIDENT IN SUCH A JURISDICTION), BEFORE YOU MAY OBTAIN ACCESS TO THE INFORMATION. THE INFORMATION IS NOT DIRECTED AT, AND IS NOT INTENDED TO BE ACCESSIBLE BY, PERSONS RESIDENT IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. IF YOU ARE NOT PERMITTED TO VIEW THE INFORMATION, OR VIEWING THE INFORMATION WOULD RESULT IN A BREACH OF THE ABOVE, OR YOU ARE IN ANY DOUBT AS TO WHETHER YOU ARE PERMITTED TO VIEW THE INFORMATION, PLEASE EXIT THIS WEBPAGE. THIS SECTION OF THE WEBSITE CONTAINS ANNOUNCEMENTS, DOCUMENTS AND INFORMATION (TOGETHER THE "INFORMATION") RELATING TO THE OFFER IN COMPLIANCE WITH THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES 2013 (THE "IRISH TAKEOVER RULES"). THE INFORMATION IS BEING MADE AVAILABLE IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY, AND ITS AVAILABILITY IS SUBJECT TO THE TERMS AND CONDITIONS SET OUT BELOW. THE INFORMATION IS NOT INTENDED TO, AND DOES NOT, CONSTITUTE OR FORM ANY PART OF AN OFFER TO SELL OR OTHERWISE DISPOSE OF OR AN INVITATION OR THE SOLICITATION OF AN OFFER TO PURCHASE OR OTHERWISE ACQUIRE ANY SECURITIES, OR THE SOLICITATION OF A VOTE OR APPROVAL PURSUANT TO THE INFORMATION OR OTHERWISE. ANY PERSON SEEKING ACCESS TO THIS SECTION OF ABBVIE’S WEBSITE REPRESENTS AND WARRANTS TO ABBVIE THAT THEY ARE DOING SO FOR INFORMATION PURPOSES ONLY. BASIS OF ACCESS TO INFORMATION Please read this notice carefully before clicking "I agree" or "I disagree" below. This notice applies to all persons who view this section of the website and, depending on where you live, it may affect your rights. This notice may be amended or updated by AbbVie from time to time and it should be read carefully in full each time you wish to view the website. In addition, the content of the website, and its accessibility by certain persons, may be amended at any time in whole or in part at the sole discretion of AbbVie. The Information speaks only at the date of the relevant document or announcement and AbbVie has, and accepts, no responsibility or duty to update any Information (other than to the extent such duty arises as a matter of law or regulation). For regulatory reasons we have to ensure you are aware of the appropriate regulations for the country which you are in. To allow you to view details relating to the Offer, you have to read the following and then press "I agree". If you are unable to agree you should press "I disagree" and you will not be able to view any such details. OVERSEAS PERSONS The Information is not for publication or distribution, directly or indirectly, in or into any jurisdiction where it would be unlawful to do so. The Information is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any votes attaching to securities which are the subject of the Offer in any jurisdiction in which such offer, solicitation or invitation is unlawful, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. In particular, the Information is not an offer of securities for sale into the United States. No offer of securities shall be made in the United States absent registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from, or in a transaction not subject to, such registration requirements. Any securities issued in the Acquisition are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act of 1933, as amended. The Information may not be downloaded or accessed by any person from or in any jurisdiction where it would or may constitute a breach of any applicable laws or regulations. If you are not permitted to view or download the Information on the website, or viewing or downloading the Information would result in a breach of the above, or you are in any doubt as to whether you are permitted to view or download the Information, please exit this webpage by clicking on the "I disagree" box below. By clicking on the "I agree" box below, you certify that you will not forward, transmit, show or distribute (by any means including by electronic transmission) the Information to any person. In particular, you certify that you will not forward or transmit the Information either in whole or in part to any person in any jurisdiction where such distribution may be restricted by applicable law or regulation. Failure to comply with any such restrictions may constitute a violation of the laws and/or regulations of any such jurisdiction. CONFIRMATION OF UNDERSTANDING AND ACCEPTANCE OF THIS NOTICE By clicking on "I agree" below, you confirm that you have read, understood and agreed to be bound by the terms of the notice set out above and that you are not in, or a resident of, any jurisdiction where to download or view the Information would constitute a breach of securities law or regulation in that jurisdiction. If you click "I disagree" below, we will be unable to provide you with access to the Information and you will be redirected to AbbVie’s homepage. Subject to any continuing obligations under applicable law or any relevant regulatory requirements, AbbVie expressly disclaims any obligation to disseminate, after the date of the posting of any document or announcement on this webpage, any updates or revisions to any statements in such documents or announcements in relation to the Offer to reflect any change in expectations or events, conditions or circumstances on which any such statements are based. If you are in any doubt about the contents of this section of the website or the action you should take, you should seek your own financial advice from an appropriately authorised independent financial adviser.